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Abstract
 
Fc
 
 
 
RIIB is a potent lupus susceptibility gene as demonstrated by the observation that mice defi-
cient in this molecule develop spontaneous antinuclear antibodies (ANA) and fatal glomerulone-
phritis when on the C57BL/6 background. To determine the mechanisms underlying the epistasis
 
displayed by this gene we have constructed hybrids between Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 and the systemic lupus
 
erythematosus (SLE) modifiers 
 
yaa
 
 and 
 
lpr
 
 and the susceptibility locus 
 
Sle1
 
. 
 
Sle1
 
 and B6.RIIB
 
 
 
/
 
 
 
are both physically and functionally coupled; compound heterozygotes of 
 
Sle1
 
 and B6.RIIB
 
 
 
/
 
 
 
develop significant disease, while single heterozygotes display no evidence of autoimmunity or
disease, indicating that these genes lie on the same genetic pathway resulting in the loss of toler-
ance to nuclear antigens. However, the generation of ANA in itself is insufficient to account for
the severity of autoimmune disease in this model, as demonstrated by analysis of 
 
yaa
 
 and 
 
lpr
 
 hy-
brids. Thus, B6.RIIB
 
 
 
/
 
 
 
/lpr mice are protected from disease progression, despite equivalent titers
of ANA. In contrast, B6.RIIB
 
 
 
/
 
 
 
/y
 
aa
 
 mice have significantly enhanced disease despite reduced
ANA titers. 
 
Yaa
 
 modifies the specificity and thus the pathogenicity of the B6. RIIB
 
 
 
/
 
 
 
 ANA, by
converting them to antinucleolar antibodies. In addition to these known modifier pathways, we
have discovered two novel, recessive loci contributed by the C57BL/6 genome that are required
for the ANA phenotype, further indicating the epistatic properties of this SLE model.
Key words:
 
lpr • yaa • Sle1 • 
 
autoantibodies • glomerulonephritis
 
Introduction
 
The development of systemic autoimmunity in diseases like
systemic lupus erythematosus (SLE)
 
*
 
 require the interaction
of multiple genetic loci with environmental factors to result
in the loss of tolerance, the development of an autoreactive
repertoire, and the amplification of autoreactive cells to
produce pathogenic autoantibodies (1–4). The deposition
of these autoantibodies as immune complexes and the acti-
vation of effector mechanisms to trigger tissue pathology
require still additional genetic interactions to result in the
systemic pathology typical of these diseases. Recent studies
in both rodents and humans have begun to clarify some of
the genetic interactions that underlie autoimmune disease
susceptibility and progression (for a review, see reference
5). Two types of studies have been undertaken to identify
these genetic components – classic linkage analysis in mul-
tiplex SLE families and lupus-prone inbred mouse strains;
and candidate gene analysis in human patient populations
and animal models via genomic manipulation.
Genetic studies in susceptible human or murine popula-
tions have demonstrated that disease susceptibility is multi-
factorial, involving complex interactions among several
genes together with poorly defined environmental factors
(4). While the contribution of the MHC to lupus suscepti-
bility has been well documented by numerous studies (6,
7), the importance of non-MHC loci that either increase or
suppress susceptibility to lupus has recently been appreci-
ated. A total of 31 susceptibility loci have thus been de-
fined, distributed among 21 nonoverlapping genomic in-
tervals, further indicating the genetic complexity involved
in autoimmune diseases like lupus (4). Syntenic loci have
been identified in the mouse and human for lupus suscepti-
bility on mouse chromosomes 1, 5, 6, 7, and 18. The distal
region of chromosome 1 is perhaps the best characterized
with the identification of a cluster of loci including 
 
Sle1
 
,
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Abbreviations used in this paper:
 
 ANA, antinuclear antibodies; SLE, sys-
temic lupus erythematosus. 
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RIIB
 
Nba2
 
,
 
 Bxs3
 
, and 
 
Lbw7
 
 involved in antinuclear antibody
production (8–10). 
 
Sle1
 
, for example, was derived from the
autoimmune strain NZM 2410 as a 37 cM region of
chromosome 1 from NZW (11). C57BL/6 mice congenic
for 
 
Sle1
 
 develop antichromatin autoantibodies and will
progress to autoimmune disease when combined with
other NZM-derived loci. 
 
Sle1
 
 has been further subdivided
into four distinct, although functionally related regions,
designated 
 
Sle1a
 
, 
 
b
 
,
 
 c
 
, and 
 
d
 
 (12). Although each of these
genes will express an autoimmune phenotype when iso-
lated from the others, their autoimmune phenotype is
strongly enhanced when they are expressed in combina-
tion, suggesting that they may impact a common pathway
leading to the loss of tolerance to nuclear antigens (13).
In a second type of study, candidate genes have been
modified in unaffected mouse strains to determine their
contribution to disease susceptibility. A common theme has
emerged from these studies highlighting the central role of
inhibitory molecules in maintaining tolerance to nuclear
antigens. For example, deletion of the inhibitory surface
molecules CD22, cytotoxic T lymphocyte antigen 4, PD-1,
or Fc
 
 
 
RIIB result in animals with autoimmune pheno-
types of differing degrees of severity; references 14–17).
Similarly, deletion of the inhibitory signaling molecules src
homology 1, cbl-b, or lyn also results in autoimmunity and
disease (18–21). These studies further support the threshold
nature of autoimmunity and emphasize the importance of
preventing inappropriate lymphocyte stimulation at sub-
threshold levels of antigen.
The central role of autoantibodies and immune complexes
in the pathophysiology of autoimmune diseases like lupus
has focused attention on the role of cellular receptors for
these pathogenic ligands. The Fc receptors for IgG, Fc
 
 
 
Rs,
by transducing signals from the IgG immune complex to
APCs, B cells, and effector cells, are responsible for much of
the immune responses triggered by these ligands (22). Acti-
vation Fc
 
 
 
Rs, like Fc
 
 
 
RIII, are responsible for triggering
effector cell responses to cytotoxic IgGs or immune
complexes; deletion of this receptor protects mice from au-
toimmune disease initiated by cytotoxic IgG antibodies or
immune complex deposition (23). Conversely, the inhibi-
tory Fc
 
 
 
R, Fc
 
 
 
RIIB, prevents inappropriate activation of
effector responses; its deletion renders animals hyperrespon-
sive to sub-threshold levels of cytotoxic antibodies and im-
mune complexes (24, 25). Expression of Fc
 
 
 
RIIB on B cells
and APCs plays a critical role in the maintenance of periph-
eral tolerance. Deletion of Fc
 
 
 
RIIB results in autoantibody
production in animals presented with potentially cross reac-
tive antigens, like collagens type II or IV or when modified
by specific genetic backgrounds, like C57BL/6 (17, 26, 27).
This epistatic property of the Fc
 
 
 
RIIB deficiency model of
SLE mimics the multigenic nature of human SLE.
To investigate the mechanisms that contribute to the loss
of tolerance and disease progression by Fc
 
 
 
RIIB deficiency,
we have pursued genetic studies aimed at dissecting the in-
teractions that are responsible for these phenotypes. In this
study, we have constructed hybrids between B6.RIIB
 
 
 
/
 
 
 
and the Sle1 susceptibility locus or the SLE modifiers 
 
yaa
 
and lpr and analyzed autoantibody production and disease
progression. Sle1 and B6.RIIB
 
 
 
/
 
 
 
 lie on a common genetic
pathway that results in the loss of tolerance to nuclear anti-
gens. The pathogenicity of these autoantibodies leading to
disease progression is determined by loci such as 
 
yaa
 
 and 
 
lpr
 
,
independent of autoantibody titer. Yaa enhances disease by
changing the specificity of the autoantibodies generated,
while 
 
lpr
 
 uncouples autoantibody production from autoim-
mune disease thus preventing disease progression. The im-
portance of epistasis is further emphasized by the identifica-
tion of two novel, recessive loci on B6 that are required for
antinuclear antibody production by Fc
 
 
 
RIIB. These studies
demonstrate the relevance of the B6.RIIB
 
 
 
/
 
 
 
 model to the
genetics of human SLE and reveal some of the mechanisms
required for the manifestation of SLE.
 
Materials and Methods
 
Mice.
 
Mice were maintained in SPF conditions at the Rock-
efeller University Animal Facility. The production and character-
ization of Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 and B6.
 
Sle1
 
 mice has been described pre-
viously (11, 12, 17, 35). B6 
 
yaa
 
 and B6 
 
lpr/lpr
 
 mice were
purchased from the Jackson ImmunoResearch Laboratories and
then crossed into Fc
 
 
 
RIIB
 
 
 
/
 
 
 
 and B6.
 
Sle1
 
 mice to produce
B6.
 
R2
 
 
 
/
 
 
 
 yaa, 
 
R2
 
 
 
/
 
 
 
lpr/lpr
 
, and B6.
 
Sle1yaa
 
 mice. For the F2
analysis, B6.
 
R2
 
 
 
/
 
 
 
 
 
and BALB.
 
R2
 
 
 
/
 
 
 
 mice were bred to produce
21 F1 mice, which were bred among themselves to obtain 210 F2
mice. Nine F2 mice died at an age
 
  
 
4 mo and they were dis-
carded from the study. All the new strains were maintained for 10
mo with monthly bleeding to check for antinuclear antibodies
(ANA)
 
 
 
and proteinuria. Spleen weight was measured postmortem
at 10 mo of age. Moribund animals (
 
 
 
500 mg/dL proteinuria
and 
 
 
 
40% hematocrit) were killed before the 10 mo deadline
and were counted as deceased. H2 congenic animals were pur-
chased from Jackson ImmunoResearch Laboratories.
 
Phenotypic Analysis.
 
ANA was tested using 12-well micro-
scope slides covered with human Hep-2 cells. Slides were
blocked for 10 min with PBS containing 5% goat serum (Sigma-
Aldrich) and then incubated with mouse serum at the indicated
dilutions. After two washes of 5 min with PBS, FITC-labeled
anti–mouse IgG was added at 1 
 
 
 
g/ml for 15 min and washed
away with PBS for 5 min at least three times. ANA scored was
measured as follows: 0,
 
 
 
no staining at 1:100 dilution; 1, faint
staining at 1:100; 2, bright staining at 1:100; 3, bright staining at
1:1,000; and 4,
 
 
 
bright staining at 1:10,000. Proteinuria was mea-
sured using urinalysis dip-sticks (Merck) and graded as 0,
 
  
 
50
mg/dL; 1,
 
 
 
50 mg/dL; 2, 100 mg/dL; 3, 500 mg/dL; and 4, 
 
 
 
500
mg/dL. Histological analysis of the kidneys of 80 animals was
performed and indicated a strong correlation between proteinuria
and glomerulonephritis.
 
Genetic Analysis.
 
50 (B6.
 
R2
 
 
 
/
 
 
 
 
 
  
 
BALB/c.
 
R2
 
 
 
/
 
 
 
)F2 mice
that scored 
 
 
 
3 for ANA, and 44 ANA-negative mice for com-
parison, were genotyped at 81 microsatellite markers distributed
on the 19 autosomes. Linkage groups were developed using
MAPMAKER-EXP (34) as described previously (36). Statistical
analysis of linkage was performed using MAPMAKER-QTL.
Those chromosomes that contained loci showing a suggestive
linkage (1, 4, 7, 9, 12, and 17) were selected for a second more
thorough screen that included 186 mice and 40 markers (includ-
ing markers for the H2 complex), spanning the six selected
chromosomes. 
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Results
 
The Autoimmunity Induced in B6 Mice by Fc
 
 
 
RIIB Defi-
ciency Is Functionally Linked to the Sle1 Autoimmunity-promot-
ing Gene.
 
The murine Fc
 
 
 
RIIB gene is located on the
distal part of chromosome 1, at the same location where ge-
netic studies in humans and various mouse models have
identified several autoimmune susceptibility loci (Fig. 1;
reference 4). Fc
 
 RIIB /  B6 mice develop a spontaneous
SLE-like disease, raising the possibility that these suscepti-
bility loci on chromosome 1 and the Fc RIIB gene are ge-
netically or functionally linked. One of these identified sus-
ceptibility loci, the Sle1 gene cluster from the NZW strain,
leads to ANA production in the B6 background (11). To
test for a genetic interaction between Sle1 and Fc RIIB,
(B6.Sle1   B6.R2 / ) F1 hybrids were produced and ana-
lyzed for an autoimmune phenotype. As shown in Fig. 2,
both parental strains demonstrate their previously reported
phenotypes: severe lupus disease in B6.R2 /   animals
(100% of the mice with ANA and enlarged spleen, 50%
with glomerulonephritis leading to proteinuria) and mild
disease in B6.SleI mice (30% ANA and enlarged spleen, 0%
proteinuria). Both B6.R2 /  and B6.Sle1 have predomi-
nantly recessive phenotypes with low but detectable levels
of ANA production and minimum splenomegaly or pro-
teinuria as heterozygotes. (B6.Sle1   B6.R2 / ) F1 mice,
which should be equivalent to a double heterozygote for
the Fc RII mutation and Sle1, displayed a stronger pheno-
type than either heterozygote alone or SleI homozygote. As
shown in Fig. 2, their autoimmune phenotype was equiva-
lent in disease severity to the phenotype of homozygous
B6.R2 /  mice (Fig. 2 and Table I). 90% of the (B6.Sle1  
B6.R2 / ) F1 mice produced significant ANA levels (de-
tectable at 102 serum dilution) and  10% further displayed
symptoms of severe glomerulonephritis (at least 100 mg/dL
protein in urine). These data, together with the fine map-
ping of the Sle1 region (unpublished data), placing Fc-
 RIIB outside of the four Sle1 susceptibility genes (Fig. 1)
and the observation that Fc RIIB levels are normal in both
NZW and B6.Sle 1 (data not shown), suggests that Sle 1
and Fc RIIB are nonallelic and noncomplementing and in-
teract synergistically in a dosage-dependent manner to
maintain tolerance. These studies also suggest that Sle1, like
Fc RIIB, is a negative regulator of B cell responsiveness
and that the products of these loci interact within a com-
mon pathway. A likely candidate for this pathway is the src
homology 2 domain–containing inositol polyphosphate 5 -
phosphatase inhibitory signaling pathway, which is known
to mediate the Fc RIIB signal. This might occur if the
products of the Sle 1 locus modulated either Fc RIIB ex-
pression or src homology 2 domain–containing inositol
polyphosphate 5 -phosphatase signaling thus changing the
responsiveness of B cells to antigen stimulation.
The yaa Gene Enhances the Severity of the Autoimmune Phe-
notype of B6.R2 /  Mice by Changing Autoantibody Speci-
ficity. Having determined that Sle1 and B6.RIIB /  interact
epistatically to lead to the loss of tolerance to nuclear anti-
gens and to the development of autoantibodies, we next
sought to address the role of autoantibodies in disease pro-
gression by characterizing the mechanism which genetic
modifiers, such as yaa and lpr influenced autoantibody titers
and pathogenicity. The yaa (Y-chromosome autoimmune
Figure 1. Fc RIIB maps to the Sle1 locus on chromosome 1. A com-
posite map of chromosome 1 is shown, indicating the Sle1 interval and
other lupus susceptibility loci. The Fc RIIB gene (Fcgr2) is located be-
tween Sle1a and Sle1b (unpublished data).
Figure 2. Phenotypic analysis of
the F1 cross of (B6.R2 /    
B6.Sle1) for ANA, spleen weight,
and proteinuria. The parental phe-
notypes are indicated, as well as the
phenotype of the heterozygous
B6.R2 / . Dotted lines indicate the
level at which animals are considered
to be positive for a particular pheno-
type. ANA   1/100 dilution, sple-
nomegaly  140 mg, and proteinuria
 100 mg/dL.1170 Genetic Interactions of Fc RIIB
accelerator) gene can accelerate disease in males of the
BXSB, B6.CD22 / , and B6.Sle1 strains (13, 28, 29). Sim-
ilarly, when the yaa gene is transferred to males of the
B6.R2 /  strain, we observe an acceleration of autoim-
mune disease, resulting in animals that display a disease as
severe as observed in BXSB yaa males. B6.R2 / /yaa male
mice have a median survival of 4.5 mo, compared with the
9-mo median survival of B6.R2 /  mice (Fig. 3 A). 90% of
the B6.R2 / /yaa males develop massive proteinuria ( 100
mg/dL) with striking splenomegaly (Table I). The yaa mu-
tation has been shown to enhance the autoimmune pheno-
type of the Sle1 allele in a similar fashion (reference 13, and
Fig. 3 A) further pointing to a functional linkage between
Fc RIIB and Sle1. One possible cause of this acceleration
in disease in B6.R2 /  animals was suggested by analysis of
the autoantibodies produced in the B6.R2 /  /yaa mice.
The ANA produced in these mice were altered as com-
pared with the B6.R2 / parental strain. Both the ANA ti-
Table I. Autoimmune Phenotypes of Fc RIIB-deficient Mice in Different Genetic Backgrounds
n ANA (0–4) Spleen size  Proteinuria
(mg)
RII / B6 16 2.75   0.84 324   120 12/16 (75%)
RII / B6 8 0.40   0.52 123   32 0/8 (0%)
B6 SleI homo 12 0.77   0.83 142   62 0/12 (0%)
(B6 SleI   RII / B6) F1 17 2.56   0.96 150   43 4/17 (23.5%)
RII / B6 yaaa 10 0.63    0.51 484   271 9/10 (90%)
B6.yaa 8 0.13   0.35 296   128 0/8 (0%)
RII / Balb 16 0.00   0.00 120   17 0/16 (0%)
(RII-/-B6   RII / BALB) 
F1 22 0.14   0.35 111   20 0/22 (0%)
(RII-/-B6   RII / BALB) 
F2 186 0.83   1.04 148   97 19/186 (10.2%)
aTested at 5–6 mo of age because of early mortality.
Figure 3. Yaa and lpr modify the B6.R2 /  phenotype.
(A) Cumulative mortality curves for B6.R2 / , B6.Sle1,
B6, and crosses to yaa or lpr. (B) ANA titers for B6.R2 / 
crossed to yaa or lpr at 5 and 7 mo of age. (C) ANA stain-
ing patterns on Hep2 human epithelial cells for serum de-
rived from B6.R2 /  and B6.R2 /  yaa at 1:200 dilution.
See Table I for quantitation of these traits.1171 Bolland et al.
ters and the nuclear staining patterns were different in these
mice, as compared with B6.R2 /  animals (Fig. 3 B). In
place of the homogenous nuclear staining seen in B6.R2 / 
(and B6.Sle1 animals, data not shown), the yaa-modified
animals displayed a nucleolar staining pattern, typically asso-
ciated with the presence of anti-RNP autoantibodies (Fig. 3
C). This shift in autoantibody specificity may account for
the enhanced disease severity seen in these animals, despite
the reduced ANA titers. Yaa, therefore, appears to modify
B6.R2 /  by changing the specificity of the autoantibody
repertoire from antichromatin to antiribonuclearprotein
with greater pathogenic potential. The identity of the yaa
gene product and the mechanism by which yaa modifies au-
toantibody specificity has not been determined. This gene
most likely influences regulatory pathways in B cell, DCs or
macrophages, which might affect both cell proliferation, an-
tibody production and antigen presentation. A B cell intrin-
sic defect in yaa mice has been supported by cell transfer ex-
periments, but a macrophage defect can also be detected as
monocytosis from early age (28).
The lpr Gene Protects B6.RIIB /  from Autoimmune Disease
without Altering ANA Titers. In contrast to the en-
hanced disease displayed by B6.R2 / /yaa, the lpr lympho-
proliferative and autoimmune accelerator factor paradoxi-
cally reduced disease severity in the B6.R2 /  model.
While this mutation in the Fas receptor gene is known to
cause a very severe autoimmune disease in Mrl mice (30,
31), its addition to B6.R2 /  had the opposite effect. The
resulting mice had longer life spans than B6.R2 /  mice
with little evidence of proteinuria, despite ANA titers com-
parable to the B6.R2 /  parental strain (Fig. 3). This un-
coupling of autoantibody production from autoimmune
disease progression is suggestive of either an lpr-induced de-
fect in effector responses to autoantibodies or a protective
effect of the lpr mutation on glomeruli. The lpr mutation
may attenuate immune complex deposition or effector cell
responses to these immune complexes, thus reducing dis-
ease progression. This type of protection has been observed
in Fc RIII-deficient animals, where, for example, (NZB  
NZW) F1 animals lacking Fc RIII have normal life spans
and essentially normal kidney function despite the continu-
ing production and deposition of immune complexes in
their glomeruli (23). Alternatively, by modifying the apop-
totic pathway, the lpr mutation may protect glomeruli from
effector cell mediated inflammation, thus sparing the ani-
mals from autoimmune disease. A similar case of a protec-
tive role of the lpr mutation over some pathogenic effects of
autoimmunity has also been observed in the NOD model
for autoimmune diabetes in which the pancreatic expression
of FasR has been proposed to be required for the pathology
seen in this model (32). Similarly, both lpr and gld mutations
have been shown to inhibit autoantibody production in
pristine-induced lupus (33).
Recessive B6 Genes Interact with Fc RIIB to Confer Suscepti-
bility to Autoimmune Disease. To further define the epi-
static mechanisms operating to result in SLE in the
Figure 4. Phenotypic analysis of the F2
cross (B6.R2 /    BALB.R2 / ) for ANA,
spleen weight, and proteinuria. Parental and
F1 phenotypes are shown for comparison
and summarized in Table I. Valves were
measured as in Fig. 1. 56 of the 74 ANA
positive animals displayed splenomegaly.
Figure 5. Linkage analysis for autoimmune
susceptibility loci in the B6 and BALB/c
backgrounds. Mapmaker QTL analysis per-
formed on the F2 cross (B6.R2 /    
BALB.R2 / ) gave significant LOD scores
in three chromosomes, shown as charts in
this Figure. Three loci, named sbb1, sbb2,
and sbb3 have been identified which yielded
LOD scores  3.4 and are displayed as hori-
zontal patterned bars. sbb1 is linked to sple-
nomegaly in this cross, while sbb2 and sbb3
displayed linkage for ANA at 7 mo. Tables
II and III summarize the relevant markers,
LOD scores, and inheritance pattern for
these loci.1172 Genetic Interactions of Fc RIIB
B6.RIIB /  model, we next sought to define the B6 loci
contributing to the development of disease. We have pre-
viously shown that B6.R2 /  mice develop spontaneous
SLE while BALB.R2 /  do not (17). Neither B6 nor
BALB/c wild-type mice develop noticeable spontaneous
disease. To study the impact of these background genetic
modifiers in the Fc RIIB /  disease model, a cross be-
tween B6.R2 /  and BALB.R2 /  mice was performed
and the resulting F1 and F2 generations evaluated for au-
toimmune phenotypes. Three different autoimmune traits
were measured in these mice: ANA at 7 mo and spleen
weight and proteinuria at 10 mo (Fig. 4, Table I). ANA
measurements were scored 0 to 4 as the log of the highest
dilution that gives a positive result in an ANA test. As we
have observed in previous studies, all B6.R2 /  mice were
positive at or above the 102 dilution, while all BALB.R2 / 
mice were negative even at the lowest dilution.
(B6.R2 /    BALB.R2 / ) F1 mice were protected from
disease in all three traits measured. None of the F1 animals
had ANA titers at or above the 102 dilution in the ANA
score. Spleen weight was normal and no proteinuria was
detected. Based on this result, the most influential suscepti-
bility genes from B6 were expected to be recessive, or
conversely, some BALB/c resistant alleles were expected
to be dominant. To further define these B6 or BALB-
derived loci, 186 F2 mice were evaluated for these same
three phenotypic traits. 37% of the animals scored positive
for ANA and 10% for proteinuria at 100 mg/dL or more.
The number of ANA positive F2 mice was more than
what would be expected from a single recessive susceptible
locus coming from the B6 genome. It is possible that sev-
eral combinations of susceptibility genes can produce the
ANA positive phenotype, or that the BALB/c genome
contains susceptibility genes that in BALB/c mice are neu-
tralized by resistant genes. The small number of F2 mice
with high levels of proteinuria suggested that this pheno-
typic trait resulted from the contribution of a larger num-
ber of susceptibility genes.
Localization of Autoimmune Susceptibility Loci in B6 and
BALB/c Backgrounds. 94 F2 mice with extreme scores in
the ANA test (44 with 0 and 50 with 3–4 score) were se-
lected for an initial linkage analysis. These 94 genomes
were mapped with 81 microsatellite markers that span the
Table II. Loci Associated with Autoimmune Phenotypes by a Genome Scan of (R2 / B6   R2 / BALB) F2 Progeny (188 Mice)
(Balb) (Het) (B6) Lod Lod Lod Lod Fix c17 % Gen
cM Marker AAa AB BB Free Dom. Rec. Add. Lod free Variance
ANA (0–4) 66.7 D1Mit90 0.65 1.19 1.38 2.24 2.01 0.81 1.98 2.30 5.8
10.9 D7Mit117 1.28 0.83 0.61 1.98 1.64 0.90 1.86 2.57 4.8
13.1 D9Mit67 1.10 0.81 068. 0.84 0.73 0.33 0.79 ND 2.1
33.9 D9Mit32 1.24 0.68 0.82 1.78 1.69 0.04 0.79 3.20 4.5
5.5 D12Mit12 0.48 0.79 1.37 3.87 1.80 3.19 3.67 4.32 9.1
5.5 D17Mit198 0.8 0.54 1.58 7.58 0.04 7.09 3.03 - 17.1
Spleen weight (mg) 66.7 D1Mit90 123.30 144.08 192.96 0.81 0.22 0.74 0.087 ND 4.2
10.9 D7Mit117 142.55 145.07 148.85 0.02 0.01 0.02 0.03 ND 0.1
13.1 D9Mit67 201.91 129.52 137.91 3.59 3.54 0.12 1.81 3.96 9.0
33.9 D9Mit32 209.94 135.07 131.90 2.43 2.42 0.81 1.69 ND 11.3
5.5 D12Mit12 122.47 114.47 139.24 0.14 0.09 0.09 0.14 ND 0.4
5.5 D17Mit198 130.94 138.62 196.16 2.68 0.46 2.64 2.01 - 6.8
Proteinuria (0–4) 10.9 D7Mit117 0.70 0.16 0.20 1.90 1.88 0.16 0.95 ND 6.8
13.1 D9Mit67 0.26 0.31 0.34 0.15 0.00 0.13 0.04 ND 0.4
33.9 D9Mit32 0.23 0.11 0.43 1.02 0.00 0.90 0.36 ND 2.6
5.5 D12Mit12 0.18 0.24 0.56 1.44 0.17 1.44 0.94 ND 3.5
5.5 D17Mit198 0.21 0.35 0.86 3.62 0.92 3.43 3.05 - 8.6
aAverage value of the trait for BALB homozygous at that locus.
Table III. New Autoimmune Susceptibility B6   BALB
(sbb) Loci
Trait Locus Chromosome Interval 
Lod
free
Susceptible
allele
(cM)
ANA (0–4) sbb2 Chr.12 2.5–8.5 3.87 B6
sbb3 Chr.17 5.5–23.5 7.58 B6
Spleen weight 
(mg) sbb1 Chr.9 0.0–14.0 3.59 BALB/c
Proteinuria (0–4) sbb3 Chr.17 5.5–15.5 3.62 B61173 Bolland et al.
entire mouse genome at a coverage of 20 cM. Analysis of
these data by MAPMAKER/QTL (34), indicated that chro-
mosomes 1, 4, 7, 9, 12, and 17 were likely to contain re-
gions with positive linkage for ANA. These chromosomes
were selected for more refined analysis in which all 186 F2
mice, 40 microsatellite markers and all three phenotypic
traits defined in the previous section were evaluated. Table
II shows a selection of these results, emphasizing the three
regions on chromosomes 9, 12, and 17 that gave LOD
scores of  3.4, which can be considered statistically signifi-
cant according to reference 37 (see Table II and Fig. 5).
The strongest effect came from a proximal region on chro-
mosome 17 defined by the marker D17Mit198, yielding
scores 7.58 for ANA, 3.62 for proteinuria, and 2.68 for
spleen size. In this locus, the B6 allele provides the suscep-
tibility in a recessive form for all three traits. The minimum
interval that contains the susceptibility gene/s was calcu-
lated to be 18 cM (5.5–23.5 cM distance from the telo-
mere) for ANA and 10 cM for proteinuria (5.5–15.5 cM)
(Table III). These intervals were called sbb3 (for ANA) and
sbb3a (for proteinuria). sbb3 contains the mouse H2 com-
plex, which was already shown to be critical in other
mouse models of lupus. However, proteinuria, a severe dis-
ease trait, mapped at least 4 cM centromeric to the H2
complex. To determine the contribution of the BALB/c or
B6 H2 complex on this model of lupus, we performed a
locus swap between B6.R2 /  and BALB.R2 /  mice to
get a better sense of the requirement for a specific H2 hap-
lotype in this disease model. When H2d (BALB/c carries
H2d) was bred onto B6.R2 /  mice in homozygous form,
ANA production was reduced, but proteinuria could not
be detected (data not shown). Conversely, when the re-
verse H2 swap was generated (BALB. R2 /  H2b mice),
the autoimmunity was undetectable with all three pheno-
types still below the threshold of significant values (data not
shown). Thus, the presence of the H2d haplotype provides
some protection for severe autoimmune disease but the
H2b haplotype is insufficient to initiate autoimmunity in
BALB.R2 / , supporting our mapping of the chromosome
17 locus responsible for severe disease to lie outside of the
H2 locus.
A second strong linkage (lod 3.87) was observed on
chromosome 12 for the ANA phenotype (Table II). As in
the case of the chromosome 17 locus, susceptibility is me-
diated by an allele derived from the B6 background. Anal-
ysis of the inheritance of this susceptibility among F2
progeny suggests that it contributes to susceptibility in an
allele dose manner, (intermediate for heterozygotes, com-
plete for homozygotes). The interval containing this allele
was calculated to be 6 cM (2.5–8.5 cM) and was named
sbb2 (Table III). A third significant genetic linkage was
found on chromosome 9 (lod 3.62) for the splenomegaly
trait. A 14-cM interval on the distal portion of chromo-
some 9 was found to include this susceptibility allele,
which is derived from the BALB/c background in reces-
sive form and has been named sbb1. Other loci with mi-
nor linkage for ANA were found on chromosome 1
(D1Mit60) and 7 (D7Mit117) (Table I). So far no obvious
candidate genes have been found in any of these newly
identified genomic intervals, thus increasing the likeli-
hood that fine mapping of these loci will lead to the iden-
tification of novel genes that modify susceptibility of au-
toimmune disease.
Discussion
The sequence of events that result in the lupus pheno-
type are the result of distinct genetic interactions between
susceptibility loci and their modifiers. We have dissected
the mechanisms of this epistasis in the B6.RIIB /  model
of lupus, a model that mimics many aspects of the genetics
of the human disease. Loss of tolerance to nuclear antigens
in this model involves interactions of genes lying on the
same pathway, a pathway that includes RIIB and Sle1, re-
sulting in the appearance of ANA. The pathogenicity of
these antibodies, in turn, is influenced by genes such as yaa
and lpr, yaa enhances disease by altering the specificity of
the autoantibodies despite a reduction in total titer. In con-
trast, the lpr mutation protects animals from the potentially
pathogenic effects of B6.R2 /   induced autoantibodies,
without affecting ANA titers, thus acting like a suppressor
locus in this disease model. The results indicate that modu-
lation of Fc RIIB expression or signaling is a critical step in
regulating B cell responsiveness. Thus, the inappropriate
activation of B cells, which occur when RIIB expression is
reduced or signaling is impaired will result in the loss of tol-
erance and development of autoimmunity.
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